KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $2.3 million.

  • Esperion Therapeutics' Share-based Compensation fell 2227.0% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 1503.14%. This contributed to the annual value of $12.0 million for FY2024, which is 29.27% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Share-based Compensation of $2.3 million as of Q3 2025, which was down 2227.0% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Share-based Compensation ranged from a high of $8.6 million in Q2 2021 and a low of $2.3 million during Q3 2025
  • Its 5-year average for Share-based Compensation is $3.7 million, with a median of $3.2 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 1607.84% in 2021, then plummeted by 5891.19% in 2022.
  • Esperion Therapeutics' Share-based Compensation (Quarter) stood at $4.5 million in 2021, then dropped by 16.96% to $3.7 million in 2022, then decreased by 21.4% to $2.9 million in 2023, then decreased by 3.94% to $2.8 million in 2024, then decreased by 16.26% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.7 million for Q2 2025, and $2.5 million during Q1 2025.